IP Library Granted Patent US 12,331,096
Granted Patent B2
US 12,331,096 · App. 17/415,190 · Granted Jun 17, 2025

Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto

Inventors: Lance Liotta (Fairfax, VA); Alessandra Luchini Kunkel (Fairfax, VA); Amanda Still (Fairfax, VA); Mikell Paige (Fairfax, VA)
Assignee: George Mason Research Foundation, Inc.
C07K14/70532A61P35/00C07C303/22C07C309/50C07K7/06C07K7/08C07K14/70521G01N33/6845A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,096
App. No.
17/415,190
Granted
Jun 17, 2025
Kind
B2
Abstract

The present disclosure relates to compounds, complexes, compositions, kits and methods for determining interacting and/or binding sites between e.g., proteins, proteins and nucleic acids, proteins and small molecules, or intrachain protein domains. The disclosure provides rapid and direct positive identification of the contact interface region between such molecules, and can be applied to individual interacting pairs, as well as large-scale or global interactions.

Claims (8)

1. A peptide comprising the amino acid sequence set forth as:

CYRAMISYGGADYKRITC (SEQ ID NO:2);

CLKYDAPAFTVTC (SEQ ID NO:4); or

CLNWYRMSPSNQTDKLAAC (SEQ ID NO:7).

2. A method for preventing or disrupting an interaction between a programmed death 1 (PD-1) and a programmed death ligand 1 (PD-L1), the method comprising contacting PD-1 or PD-L1 with the peptide of claim 1 before, concomitant with, or after the interaction between PD-1 and PD-L1.

3. A peptide comprising the amino acid sequence set forth as: CYRAMISYGGADYKRITC (SEQ ID NO:2).

4. A peptide comprising the amino acid sequence set forth as: CLKYDAPAFTVTC (SEQ ID NO:4).

5. A peptide comprising the amino acid sequence set forth as: CLNWYRMSPSNQTDKLAAC (SEQ ID NO: 7).

Continuity (2)
Provisional Application 62788214 · Jan 4, 2019
Related Publication 20220064259A1 · Mar 3, 2022
References Cited (19)
US 2612494A · Von et al. · 1952 [cited by applicant]
US 3086833A · Clemens · 1963 [cited by applicant]
US 4163675A · Hirano et al. · 1979 [cited by applicant]
US 4325908A · Scheinthal et al. · 1982 [cited by applicant]
US 4395264A · Fenwick · 1983 [cited by applicant]
US 10126304B2 · Luchini et al. · 2018 [cited by applicant]
US 20130137112A1 · Patton et al. · 2013 [cited by applicant]
US 20140286952A1 · Shah · 2014 [cited by applicant]
US 20150017194A1 · Akahata · 2015 [cited by examiner]
US 20170205669A1 · Ono et al. · 2017 [cited by applicant]
US 20210371496A1 · Desallais · 2021 [cited by examiner]
CN 110478472A · 2019 [cited by examiner]
WO 2014113433A1 · 2014 [cited by applicant]
English translation of CN-110478472-A. [retrieved on Mar. 21, 2024] Retrieved from Google Patents using <URL: https://patents.google.com/patent/CN110478472A/en?oq=CN110478472> (Year: 2024). [cited by examiner]
HPD-1 [ [cited by examiner]
Programmed cell death 1 ligand 1 isoform a precursor [ [cited by examiner]
MAG: DNA (cytosine-5-)-methyltransferase [Candidatus Omnitrophica bacterium] GenBank: MBU4311201.1 (Year: 2025). [cited by examiner]
International Search Report and Written Opinion mailed Jun. 4, 2020, PCT/US2020/012196. [cited by applicant]
Ali-Shtayeh , et al., “In-vitro screening of acetylcholinesterase inhibitory activity of extracts from Palestinian indigenous flora in relation to the treatment of Alzheimer's disease.”, Functional Foods in Health and D… [cited by applicant]